Abstract
Introduction: Nail psoriasis occurs in 50%-70% of patients with psoriasis (PsO) and 60%- 80% of patients with psoriatic arthritis (PsA). Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has proven highly efficacious in the long-term treatment of the multiple manifestations of psoriatic disease, with a favorable safety profile. Here, we report the long-term results of post hoc analyses of clearing (ie achieving clear or almost clear) nail psoriasis from the secukinumab PsA FUTURE program, and from the PsO TRANSFIGURE study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
